Document Type : Original articles


Department of Heet Education, General Directorate of Education in Anbar, Ministry of Education, Hit, Anbar, Iraq.


Background: Wilson disease (WD) is a genetic disorder (autosomal recessive) that affects copper metabolism. A favorable prognosis for WD can be achieved with early diagnosis and treatment. It is also strongly advised to conduct a family screening.
Objective: To find the relationship between genotype and phenotype to facilitate the diagnosis of the disease as well as using modern methods in diagnosing WD.
Methods: This study included nine WD patients and fifteen healthy participants. Members of patients with WD and healthy members provided whole blood. Blood DNA was extracted, and Exon 14 was amplified using specific primers using polymerase chain reaction (PCR). The results of the PCR products were aligned to the published human genome database using the BLAST tool.
Results: Three different variations have been recorded as a result of the experiment. All of the changes point to a deficiency in the ATP7B protein, which has been identified as a cause of WD.
Conclusions: The ATP7B gene mutation spectrum in Iraqi patients has been enhanced as a result of our research, and this information could be used to develop gene therapy and clinical/prenatal diagnosis to prevent WD in Iraq.


Main Subjects

[1]      M. Mathur, E. Singh, T. B. Poduval, and A. V. Rao, “Development of low-density oligonucleotide microarrays for detecting mutations causing Wilson’s disease,” Indian J. Med. Res., vol. 141, no. 2, p. 175, 2015.
[2]      C. Chen, B. Shen, J.-J. Xiao, R. Wu, S. J. D. Canning, and X.-P. Wang, “Currently clinical views on genetics of Wilson’s disease,” Chin. Med. J. (Engl)., vol. 128, no. 13, pp. 1826–1830, 2015.
[3]      A. Chanpong and A. Dhawan, “Wilson disease in children and young adults-State of the art,” Saudi J. Gastroenterol. Off. J. Saudi Gastroenterol. Assoc., vol. 28, no. 1, p. 21, 2022.
[4]      J. O. T. Sipilä, L. Kytövuori, and V. Kaasinen, “Clinical spectrum and genotype-phenotype associations in Finnish patients with Wilson’s disease,” J. Neurol. Sci., vol. 448, p. 120620, 2023.
[5]      G. Gromadzka, M. Bendykowska, and A. Przybyłkowski, “Wilson’s disease—Genetic puzzles with diagnostic implications,” Diagnostics, vol. 13, no. 7, p. 1287, 2023.
[6]      R. Cocoş, A. Şendroiu, S. Schipor, L. C. Bohîlţea, I. Şendroiu, and F. Raicu, “Genotype-phenotype correlations in a mountain population community with high prevalence of Wilson’s disease: genetic and clinical homogeneity,” PLoS One, vol. 9, no. 6, p. e98520, 2014.
[7]      M. Quinodoz et al., “Analysis of missense variants in the human genome reveals widespread gene-specific clustering and improves prediction of pathogenicity,” Am. J. Hum. Genet., vol. 109, no. 3, pp. 457–470, 2022.
[8]      P. Socha et al., “Wilson’s disease in children: a position paper by the Hepatology Committee of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition,” J. Pediatr. Gastroenterol. Nutr., vol. 66, no. 2, pp. 334–344, 2018.
[9]      A. J. Coffey et al., “A genetic study of Wilson’s disease in the United Kingdom,” Brain, vol. 136, no. 5, pp. 1476–1487, 2013.
[10]     P. Ferenci et al., “Age and sex but not ATP7B genotype effectively influence the clinical phenotype of Wilson disease,” Hepatology, vol. 69, no. 4, pp. 1464–1476, 2019.
[11]     C. E. Mordaunt et al., “Epigenomic signatures in liver and blood of Wilson disease patients include hypermethylation of liver-specific enhancers,” Epigenetics Chromatin, vol. 12, no. 1, pp. 1–16, 2019.
[12]     A. Członkowska, M. Rodo, A. Wierzchowska‐Ciok, L. Smolinski, and T. Litwin, “Accuracy of the radioactive copper incorporation test in the diagnosis of Wilson disease,” Liver Int., vol. 38, no. 10, pp. 1860–1866, 2018.
[13]     A. Poujois, J. Poupon, and F. Woimant, “Direct determination of non-ceruloplasmin-bound copper in plasma,” in Clinical and translational perspectives on Wilson disease, Elsevier, pp. 249–255, 2019.
[14]     K. H. Weiss et al., “Bis-choline tetrathiomolybdate in patients with Wilson’s disease: an open-label, multicentre, phase 2 study,” Lancet Gastroenterol. Hepatol., vol. 2, no. 12, pp. 869–876, 2017.
[15]     M. Leung, J. Wu Lanzafame, and V. Medici, “Switching pharmacological treatment in Wilson disease: case report and recommendations,” J. Investig. Med. high impact case reports, vol. 8, p. 2324709619896876, 2020.
[16]     B. Gul, S. Firasat, R. Tehreem, T. Shan, and K. Afshan, “Analysis of Wilson disease mutations in copper binding domain of ATP7B gene,” PLoS One, vol. 17, no. 6, p. e0269833, 2022.
[17]     F. Maghool et al., “Rescue effect of curcumin against copper toxicity,” J. Trace Elem. Med. Biol., p. 127153, 2023.
[18]     C. Weyh, K. Krüger, P. Peeling, and L. Castell, “The role of minerals in the optimal functioning of the immune system,” Nutrients, vol. 14, no. 3, p. 644, 2022.
[19]     S. Shribman et al., “Investigation and management of Wilson’s disease: a practical guide from the British Association for the Study of the Liver,” Lancet Gastroenterol. Hepatol., 2022.
[20]     S. Jia et al., “Laboratory and clinical evaluation of a microarray for the detection of ATP7B mutations in Wilson disease in China,” J. Clin. Lab. Anal., vol. 36, no. 11, p. e24735, 2022.
[21]     F. Zolfizadeh et al., “Factors Associated with Infant Mortality due to Congenital Anomalies: A Population-Based Case-Control Study,” Iran. J. Public Health, vol. 51, no. 5, p. 1118, 2022.
[22]     D. R. P. Hiremath, D. R. M. L. S. Nair, D. R. R. P. Patange, D. R. J. Salunkhe, D. R. P. Naregal, and M. A. Mulani, “Relation between Gender, Birth Outcomes, Gestational Age and Gravida with Congenital malformation,” J. Pharm. Negat. Results, pp. 5940–5945, 2022.
[23]     T. Yasmin, E. M. Andres, K. Ashraf, M. A. R. Basra, and M. H. Raza, “Genome-wide analysis of runs of homozygosity in Pakistani controls with no history of speech or language-related developmental phenotypes,” Ann. Hum. Biol., vol. 50, no. 1, pp. 100–107, 2023.
[24]     V. Lodato et al., “Cardiomyopathies in Children and Systemic Disorders When Is It Useful to Look beyond the Heart?,” J. Cardiovasc. Dev. Dis., vol. 9, no. 2, p. 47, 2022.
[25]     O. Q. Yaseen, M. Q. Al-Ani, and Y. H. Majeed, “In-Silico prediction of impact on protein function caused by non-synonymous single nucleotide polymorphism in human ATP7B gene associated with Wilson disease,” Res. J. Biotechnol. Vol, vol. 15, p. 3, 2020.
[26]     R. Tasmeen et al., “Mutational analysis of exon 8 and exon 14 of ATP7B gene in Bangladeshi children with Wilson disease,” Indian J. Gastroenterol., vol. 41, no. 5, pp. 456–464, 2022.
[27]     D. Xiong, D. Lee, L. Li, Q. Zhao, and H. Yu, “Implications of disease-related mutations at protein–protein interfaces,” Curr. Opin. Struct. Biol., vol. 72, pp. 219–225, 2022.
[28]     P. Lei, S. Ayton, and A. I. Bush, “The essential elements of Alzheimer’s disease,” J. Biol. Chem., vol. 296, 2021.
[29]     B. A. Kanaan, M. T. S. Al-Ouqaili, and R. M. Murshed, “In terms of the PCR-RFLP technique, genetic screening of Ala575Val inactivating mutation in patients with amenorrhea,” J. Emerg. Med. Trauma Acute Care, vol. 2022, no. 6, p. 8, 2022.